

Philipp B Staber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/827711/publications.pdf>

Version: 2024-02-01

103
papers

3,495
citations

172457

29
h-index

149698

56
g-index

105
all docs

105
docs citations

105
times ranked

6450
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. <i>Cancer Discovery</i> , 2022, 12, 372-387.	9.4	77
2	DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks. <i>Clinical Cancer Research</i> , 2022, 28, 756-769.	7.0	9
3	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). <i>Journal of Clinical Oncology</i> , 2022, 40, 242-251.	1.6	90
4	T-Cell Large Granular Lymphocyte Leukemia: An Interdisciplinary Issue?. <i>Frontiers in Oncology</i> , 2022, 12, 805449.	2.8	1
5	The impact of COVID-19 on cancer care of outpatients with low socioeconomic status. <i>International Journal of Cancer</i> , 2022, 151, 77-82.	5.1	15
6	New frontiers in chronic lymphocytic leukemia on the way to curing the disease. <i>Memo - Magazine of European Medical Oncology</i> , 2022, 15, 3-3.	0.5	0
7	Latent structure and measurement invariance of the Hospital Anxiety and Depression Scale in cancer outpatients. <i>International Journal of Clinical and Health Psychology</i> , 2022, 22, 100315.	5.1	6
8	CXCR4 PET imaging of mantle cell lymphoma using [⁶⁸ Ga]Pentixafor: comparison with [¹⁸ F]FDG-PET. <i>Theranostics</i> , 2021, 11, 567-578.	10.0	26
9	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2251-2256.	3.5	7
10	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. <i>HemaSphere</i> , 2021, 5, e536.	2.7	11
11	Blood cancer driver Musashi-2 as therapeutic target in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 982-983.	7.2	0
12	Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter. <i>Blood</i> , 2021, 138, 1345-1358.	1.4	12
13	Myeloid lncRNA <i>LOUP</i> mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. <i>Blood</i> , 2021, 138, 1331-1344.	1.4	19
14	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. <i>Blood</i> , 2021, 137, 3495-3506.	1.4	22
15	Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. <i>Leukemia and Lymphoma</i> , 2021, 62, 3440-3451.	1.3	6
16	EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Waldenström's Macroglobulinemia. <i>HemaSphere</i> , 2021, 5, e634.	2.7	2
17	Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. <i>Neoplasia</i> , 2021, 23, 1183-1191.	5.3	1
18	Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. <i>Cancers</i> , 2021, 13, 5592.	3.7	9

#	ARTICLE	IF	CITATIONS
19	Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial. <i>Blood</i> , 2021, 138, 2639-2639.	1.4	1
20	Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in the Large Arteries of Lymphoma Patients under 50 Years of Age. <i>Biology</i> , 2021, 10, 1206.	2.8	3
21	High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial. <i>Blood</i> , 2021, 138, 72-72.	1.4	3
22	A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RvE, GvE, GvE) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. <i>Blood</i> , 2021, 138, 71-71.	1.4	36
23	First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 3556-3556.	1.4	2
24	Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. <i>Nature Communications</i> , 2021, 12, 7190.	12.8	7
25	Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 97-109.	1.9	9
26	Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30 ⁺ aggressive lymphomas. <i>European Journal of Haematology</i> , 2020, 104, 251-258.	2.2	12
27	RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients. <i>Cancers</i> , 2020, 12, 9.	3.7	15
28	IL2RA Promotes Aggressiveness and Stem Cell-Related Properties of Acute Myeloid Leukemia. <i>Cancer Research</i> , 2020, 80, 4527-4539.	0.9	12
29	UGT2B17 modifies drug response in chronic lymphocytic leukaemia. <i>British Journal of Cancer</i> , 2020, 123, 240-251.	6.4	13
30	Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL. <i>Cells</i> , 2020, 9, 1484.	4.1	7
31	The Bone ⁺ 's Role in Myeloid Neoplasia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4712.	4.1	2
32	In Human Visualization of Ibrutinib-Induced CLL Compartment Shift. <i>Cancer Immunology Research</i> , 2020, 8, 984-989.	3.4	7
33	Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 32-33.	1.4	20
34	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. <i>Blood</i> , 2020, 136, 2-4.	1.4	1
35	Evi1 Counteracts Anti-Leukemic and Stem Cell Inhibitory Effects of All-Trans Retinoic Acid on Flt3-ITD/Npm1c-Driven Acute Myeloid Leukemia Cells. <i>Biomedicines</i> , 2020, 8, 385.	3.2	4
36	[¹⁸ F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients. <i>Cancers</i> , 2020, 12, 1138.	3.7	24

#	ARTICLE	IF	CITATIONS
37	Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells. <i>Blood</i> , 2020, 136, 40-41.	1.4	0
38	Metabolic Drug Survey Highlights Cancer Cell Dependencies and Vulnerabilities. <i>Blood</i> , 2020, 136, 26-27.	1.4	0
39	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. <i>Leukemia</i> , 2019, 33, 696-709.	7.2	40
40	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. <i>Blood</i> , 2019, 134, 1132-1143.	1.4	81
41	Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL. <i>Nature Chemical Biology</i> , 2019, 15, 232-240.	8.0	34
42	RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 350.	4.1	17
43	Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI. <i>ESMO Open</i> , 2019, 4, e000538.	4.5	7
44	All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia. <i>Cell Death and Disease</i> , 2019, 10, 944.	6.3	18
45	Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3965-3965.	1.4	1
46	Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax. <i>Blood</i> , 2019, 134, 807-807.	1.4	2
47	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial. <i>Blood</i> , 2019, 134, 2877-2877.	1.4	3
48	Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial). <i>Blood</i> , 2019, 134, 1754-1754.	1.4	7
49	Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR. <i>Blood</i> , 2019, 134, 4037-4037.	1.4	1
50	In Human Visualization of Ibrutinib-Induced CLL Compartment Shift. <i>Blood</i> , 2019, 134, 1750-1750.	1.4	0
51	Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 931-940.	6.4	23
52	[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia. <i>Investigative Radiology</i> , 2018, 53, 403-408.	6.2	45
53	Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv41-iv50.	1.2	63
54	CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. <i>Blood</i> , 2018, 132, 1936-1950.	1.4	18

#	ARTICLE	IF	CITATIONS
55	Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy. <i>Blood</i> , 2018, 132, 4433-4433.	1.4	2
56	When the guardian sleeps: Reactivation of the p53 pathway in cancer. <i>Mutation Research - Reviews in Mutation Research</i> , 2017, 773, 1-13.	5.5	47
57	Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. <i>Leukemia</i> , 2017, 31, 1117-1122.	7.2	36
58	First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. <i>Blood</i> , 2017, 130, 2499-2503.	1.4	59
59	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. <i>EBioMedicine</i> , 2017, 26, 17-24.	6.1	24
60	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. <i>Lancet Haematology</i> , 2017, 4, e595-e606.	4.6	130
61	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. <i>Nature Medicine</i> , 2016, 22, 1488-1495.	30.7	195
62	The DNA Ligase IV Syndrome R278H Mutation Impairs B Lymphopoiesis via Error-Prone Nonhomologous End-Joining. <i>Journal of Immunology</i> , 2016, 196, 244-255.	0.8	4
63	Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation. <i>PLoS ONE</i> , 2016, 11, e0156693.	2.5	11
64	ASH 2014 highlights: new therapeutic concepts for T cell lymphomas. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 176-179.	0.5	1
65	Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. <i>Cell Stem Cell</i> , 2015, 17, 611-623.	11.1	97
66	Ristocetin-Induced Platelet Aggregation for Monitoring of Bleeding Tendency in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 718-718.	1.4	3
67	Sox4 Is a Key Oncogenic Target in C/EBP β Mutant Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2014, 25, 257.	16.8	0
68	The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells. <i>Blood</i> , 2014, 124, 2391-2399.	1.4	32
69	Sox4 Is a Key Oncogenic Target in C/EBP β Mutant Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2013, 24, 575-588.	16.8	112
70	Sustained PU.1 Levels Balance Cell-Cycle Regulators to Prevent Exhaustion of Adult Hematopoietic Stem Cells. <i>Molecular Cell</i> , 2013, 49, 934-946.	9.7	127
71	C/EBP α controls acquisition and maintenance of adult haematopoietic stem cell quiescence. <i>Nature Cell Biology</i> , 2013, 15, 385-394.	10.3	121
72	PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. <i>Nature Medicine</i> , 2012, 18, 1699-1704.	30.7	113

#	ARTICLE	IF	CITATIONS
73	Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1716-1726.	2.0	55
74	Identification of Sox4 As Key Oncogene in Leukemias with Mutated or Silenced C/EBP β . <i>Blood</i> , 2012, 120, 114-114.	1.4	0
75	Sociology of Normal Stem and Progenitor Cells in CML Niche. <i>Blood</i> , 2012, 120, 1234-1234.	1.4	0
76	Runx1 Induced Chromatin Folding of the PU.1 Gene Locus Is Necessary for Adult Long-Term Hematopoietic Stem Cell Maintenance. <i>Blood</i> , 2011, 118, 2364-2364.	1.4	0
77	New and Highly Efficient Therapy for Treatment NPM-ALK Associated Lymphomas. <i>Blood</i> , 2011, 118, 1659-1659.	1.4	1
78	PU.1 Is a Downstream Target of C/EBP β in Normal Hematopoiesis and Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 1353-1353.	1.4	0
79	Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. <i>Blood</i> , 2010, 115, 2901-2909.	1.4	46
80	Translational regulation mechanisms of AP-1 proteins. <i>Mutation Research - Reviews in Mutation Research</i> , 2009, 682, 7-12.	5.5	186
81	Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. <i>Lancet Oncology</i> , The, 2009, 10, 855-864.	10.7	620
82	Autoregulation of the Transcription Factor PU.1 Via Its Evolutionarily Conserved Upstream Regulatory Element Is Critical in Adult Mouse Hematopoiesis.. <i>Blood</i> , 2009, 114, 1468-1468.	1.4	0
83	Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2008, 42, 275-279.	2.4	58
84	Posaconazole in the management of refractory invasive fungal infections. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 747-757.	2.0	25
85	MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. <i>Blood</i> , 2007, 109, 3500-3504.	1.4	68
86	Antifungal management in cancer patients. <i>Wiener Medizinische Wochenschrift</i> , 2007, 157, 503-510.	1.1	14
87	Identification of Critical Phosphorylation Sites within NPM-ALK That Regulate JUNB mRNA Translation.. <i>Blood</i> , 2007, 110, 3571-3571.	1.4	0
88	Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2203-2210.	4.1	141
89	mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma. <i>Leukemia Research</i> , 2006, 30, 343-348.	0.8	12
90	Management of sepsis in neutropenia: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2006, 85, 424-433.	1.8	41

#	ARTICLE	IF	CITATIONS
91	Two Transforming C-RAF Germ-Line Mutations Identified in Patients with Therapy-Related Acute Myeloid Leukemia. <i>Cancer Research</i> , 2006, 66, 3401-3408.	0.9	84
92	NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Exerts Its Transforming Potential by Increasing Translation of JUNB through mTOR and S6K1.. <i>Blood</i> , 2006, 108, 1428-1428.	1.4	0
93	Adding Palifermin in Allogeneic and Autologous Stem Cell Transplantation Resulted in Reduced Oral Mucositis and Enhanced Intestinal Mucosal Recovery Measured by Citrulline Serum Levels.. <i>Blood</i> , 2006, 108, 5251-5251.	1.4	0
94	NPM-ALK Converts JUNB from a Tumor Suppressor to an Oncogene.. <i>Blood</i> , 2006, 108, 1448-1448.	1.4	0
95	Aberrant Somatic Hypermutation of Follicular Lymphoma Transformed To Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2006, 108, 2413-2413.	1.4	0
96	Severe thrombocytopenia due to host-derived anti-HPA-1a after non-myeloablative allogeneic haematopoietic stem cell transplantation for multiple myeloma: a case report. <i>Vox Sanguinis</i> , 2005, 89, 257-260.	1.5	9
97	Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2005, 35, 889-893.	2.4	43
98	Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. <i>Oncogene</i> , 2004, 23, 894-904.	5.9	76
99	Genes Regulated by NPM-ALK Fusion Kinase Play a Key Role in the Activation of AP-1 Transcription Factors.. <i>Blood</i> , 2004, 104, 245-245.	1.4	7
100	Two Novel Activating Germline Mutations of the C-RAF Proto-Oncogene Predisposing to Solid Tumors and Therapy-Related Acute Myeloid Leukemia.. <i>Blood</i> , 2004, 104, 3370-3370.	1.4	0
101	Myocardial Dysfunction and Male Mortality in Peroxisome Proliferator-Activated Receptor Alpha Knockout Mice Overexpressing Lipoprotein Lipase in Muscle. <i>Laboratory Investigation</i> , 2003, 83, 259-269.	3.7	41
102	Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia. <i>Haematologica</i> , 2003, 88, ECR29.	3.5	3
103	Precision Medicine Concepts in T-Cell Lymphoma. , 0, , .		0